MDT Growth Narrative Intact, But DeepValue Report Stays Cautious on Litigation and Valuation

What happened

Medtronic's Q4 earnings call reiterated a growth trajectory for FY26 and FY27, highlighting Cardiac Ablation Solutions and new platforms as key drivers, while addressing investor concerns on tariffs and TAVR. However, the DeepValue report maintains a WAIT rating, citing the $382M Applied jury verdict with automatic trebling and $2.9B in uncertain tax reserves as material overhangs. PFA share gains remain robust—+80% worldwide YoY—but competition from Abbott Volt's FDA approval raises pricing pressure risks that could erode margins. At $95.60, the stock trades at 26.6x P/E and 16.2x EV/EBITDA, leaving minimal room for operational disappointment. The critical near-term catalyst is FY26 Q4 results on May 20, 2026, which must confirm sustained PFA momentum and provide clearer litigation posture to justify the valuation multiple.

Implication

The investment thesis hinges on two unresolved variables: PFA pricing durability as Abbott Volt commercializes, and the Applied litigation outcome that could drain cash and constrain strategy. If FY26 Q4 reaffirms share gains without price concessions and post-trial motions contain treble damages, the stock could re-rate toward $105. However, any negative surprise on PFA deceleration or an adverse legal ruling could compress the multiple to $80. Patience until the May 20, 2026 earnings print and post-trial milestones is prudent.

Thesis delta

The earnings call reinforces the existing growth narrative but does not shift the risk-reward calculus. The deep value thesis remains unchanged: wait for proof that PFA share gains persist without pricing erosion and that the Applied litigation does not escalate into a cash event. The news confirms the base-case trajectory but does not increase conviction enough to exit WAIT.